Brief: Ngm Bio Announces Presentation Of Data From Phase 2 Investigator-Sponsored Trial Of Aldafermin
08/05/2023 23:31
May 8 (Reuters) - NGM Biopharmaceuticals Inc NGM.O :
* NGM BIO ANNOUNCES PRESENTATION OF DATA FROM PHASE 2
INVESTIGATOR-SPONSORED TRIAL OF ALDAFERMIN FOR THE TREATMENT OF
PATIENTS WITH DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME
(IBS-D) AND BILE ACID MALABSORPTION (BAM) AT DIGESTIVE DISEASE
WEEK 2023
Source text for Eikon: ID:nGNX3Ydv31
Further company coverage: NGM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NGM Biopharmaceuticals
See all newsBrief: NGM Biopharmaceuticals Q4 Net Income USD -27.67 Million
Brief: NGM Bio Enters into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group
NGM Biopharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Ngm Biopharmaceuticals Says It Got Written Notice From Nasdaq Informing It Has Regained Compliance With Nasdaq Listing
Brief: NGM Bio Announces New Clinical Data From Ongoing Trial Of Ngm707 In Advanced Solid Tumors